Arrowhead Pharmaceuticals Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect seven directors named in the proxy to serve until the next annual meeting.

2. 2

   Advisory Vote to Approve Executive Compensation (Say-on-Pay

   ManagementBoard: FOR

   Non-binding advisory vote to approve the compensation of named executive officers as disclosed in the proxy.

   More detail

   The proposal requests an advisory, non-binding approval of the company’s disclosed executive compensation. Management seeks shareholder affirmation of its pay practices to validate the Compensation Committee’s approach and to demonstrate alignment with stockholder interests. The Board recommends FOR, noting that it will consider the outcome when shaping future compensation. The vote is routine, non-binding, and used by the Compensation Committee as feedback; a failure to receive support could lead to reassessment of compensation policies. The proposal ties to executive compensation disclosures including pay philosophy, mix of equity and cash incentives, PRSUs and RSUs, and clawback and holding policies. Outcome has no direct force on pay but influences governance and future decisions.

3. 3

   Approval of Amended and Restated 2021 Incentive Plan

   ManagementBoard: FOR

   Approve the Amended and Restated 2021 Incentive Plan to increase share reserve by 10,500,000 shares, extend term to January 21, 2036, and make administrative changes.

   More detail

   Proposal asks stockholders to approve an amended and restated equity incentive plan that increases the share pool by 10.5 million shares and extends the plan term to 2036. Management argues this is necessary because the current plan has limited remaining shares and no other plan exists to issue equity awards; without approval, the company would be forced to use cash compensation or other suboptimal alternatives, potentially harming retention and alignment. The plan retains governance safeguards: administration by independent Compensation Committee, minimum vesting requirements (with limited exceptions), prohibition on repricing without stockholder approval, no dividends on unvested awards, and a CEO holding period. The board considered burn rate and overhang and concluded the requested increase supports approximately five years of expected grants and aligns with compensation strategy. Voting FOR supports management’s ability to continue equity-based incentives; a vote AGAINST would constrain the company’s ability to grant equity and could materially affect recruiting and retention and increase cash compensation costs.

4. 4

   Ratification of Selection of Independent Auditors

   ManagementBoard: FOR

   Ratify the Audit Committee’s selection of KPMG LLP as the company’s independent auditors for fiscal year ending September 30, 2026.

5. 5

   Transaction of Other Matters

   ManagementBoard: FOR

   Transact any other matters properly coming before the Annual Meeting.

Upcoming shareholder meetings at Arrowhead Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Arrowhead Pharmaceuticals Inc 2026 annual meeting?

Arrowhead Pharmaceuticals Inc (ARWR) holds its 2026 annual shareholder meeting on Thursday, March 19, 2026.

What is the record date for the Arrowhead Pharmaceuticals Inc 2026 meeting?

The record date for the Arrowhead Pharmaceuticals Inc 2026 meeting is Thursday, January 22, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Arrowhead Pharmaceuticals Inc's 2026 meeting?

The board is presenting 7 director nominees at the Arrowhead Pharmaceuticals Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Arrowhead Pharmaceuticals Inc 2026 meeting?

Shareholders will vote on 5 proposals at the Arrowhead Pharmaceuticals Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.